# OneCell Diagnostics Pvt

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onecell-diagnostics-pvt

- Industry: Biotechnology
- Headquarters: Mumbai, India
- Website: www.onecelldx.com/
- Total disclosed funding: $16M
- Latest round: Series A (Nov 21, 2024)
- Investors on record: 4

## About

Founded in 2021 and based in Maharashtra, India, OneCell Diagnostics Pvt Ltd. focuses on precision oncology through advanced diagnostic solutions. Mohan Uttarwar (CEO) and Aravindan Vasudevan (COO) are the co-founders of the company. In November 2024, OneCell Diagnostics Pvt Ltd. raised USD 16 million in series A funding led by Celesta Capital, including Singularity Ventures, Tenacity Ventures, Cedars-Sinai Health System, and Eragon.

OneCell Diagnostics specializes in precision oncology through an advanced suite of diagnostic solutions aimed at enhancing cancer care. The core product offerings include OncoIndx, a genomic profiling test utilizing a 1000+ gene panel for actionable insights through AI and machine learning-enabled dynamic data analysis; OncoDiscover, an indigenously developed liquid biopsy test for detecting and enumerating circulating tumor cells (CTCs); and OncoMonitor, which provides long-term disease monitoring through novel liquid biopsy techniques. Additionally, the company offers OncoRisk, a hereditary germline cancer test that examines a panel of 74 genes related to various hereditary cancers, and OncoPredikt, an AI-driven tool predicting genomic signatures from histopathology images. These services primarily cater to oncologists, hospitals, and research institutions.

OneCell Diagnostics generates revenue through a combination of diagnostic services and partnerships with healthcare providers and research institutions. Transactions typically occur on a B2B basis, with healthcare facilities purchasing tests such as OncoIndx and OncoDiscover to facilitate patient care.

The organization plans to use the November 2024 funding to expand its operations in the U.S. market and commercialize its next-generation liquid biopsy test, OncoIndx Ikon, and further its global reach in precision cancer diagnosis and treatment.

## Funding rounds

- Series A, Nov 21, 2024, $16M — Singularity AMC, Celesta Capital, Cedars-Sinai Health System, Tenacity Ventures

## Investors

- Singularity AMC (https://capitalatlas.ai/funds/singularity-amc) — Series A
- Celesta Capital (https://capitalatlas.ai/funds/celesta-capital) — Series A
- Cedars-Sinai Health System — Series A
- Tenacity Ventures (https://capitalatlas.ai/funds/tenacity-ventures) — Series A